Reviews

< Previous         Next >  
Aberrant alternative splicing in breast cancer
Quan Yang 1,† , Jinyao Zhao 1,† , Wenjing Zhang 1,* , Dan Chen 2,* , and Yang Wang 1,*
1 Institute of Cancer Stem Cell, Dalian Medical University, Dalian 116044, China
2 Department of Pathology, First Affiliated Hospital, Dalian Medical University, Dalian 116044, China
These authors contributed equally to this work.
*Correspondence to:Yang Wang, E-mail: yangwang@dmu.edu.cn; Dan Chen, E-mail: 18098877136@163.com; Wenjing Zhang, E-mail: zhangwj@dmu.edu.cn
J Mol Cell Biol, Volume 11, Issue 10, October 2019, Pages 920-929  https://doi.org/10.1093/jmcb/mjz033
Keyword: alternative splicing, breast cancer, splicing factors, drug resistance, cancer therapeutics

Alternative splicing is critical for human gene expression regulation, which plays a determined role in expanding the diversity of functional proteins. Importantly, alternative splicing is a hallmark of cancer and a potential target for cancer therapeutics. Based on the statistical data, breast cancer is one of the top leading causes of cancer-related deaths in women worldwide. Strikingly, alternative splicing is closely associated with breast cancer development. Here, we seek to provide a general review of the relationship between alternative splicing and breast cancer. We introduce the process of alternative splicing and its regulatory role in cancers. In addition, we highlight the functions of aberrant alternative splicing and mutations of splicing factors in breast cancer progression. Moreover, we discuss the role of alternative splicing in cancer drug resistance and the potential of being targets for cancer therapeutics.